company background image
8247

Biosino Bio-Technology and Science Incorporation SEHK:8247 Stock Report

Last Price

HK$1.40

Market Cap

HK$202.6m

7D

-4.1%

1Y

15.7%

Updated

30 Jun, 2022

Data

Company Financials
8247 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

8247 Stock Overview

Biosino Bio-Technology and Science Incorporation, together with its subsidiaries, manufactures, sells, and distributes in-vitro diagnostic reagent products in Mainland China.

Biosino Bio-Technology and Science Incorporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biosino Bio-Technology and Science Incorporation
Historical stock prices
Current Share PriceHK$1.40
52 Week HighHK$1.94
52 Week LowHK$1.08
Beta0.20
1 Month Change-4.76%
3 Month Change-20.46%
1 Year Change15.70%
3 Year Change-6.67%
5 Year Change-43.78%
Change since IPO-48.62%

Recent News & Updates

Shareholder Returns

8247HK BiotechsHK Market
7D-4.1%1.5%3.1%
1Y15.7%-55.7%-21.2%

Return vs Industry: 8247 exceeded the Hong Kong Biotechs industry which returned -55.7% over the past year.

Return vs Market: 8247 exceeded the Hong Kong Market which returned -21.2% over the past year.

Price Volatility

Is 8247's price volatile compared to industry and market?
8247 volatility
8247 Average Weekly Movement1.9%
Biotechs Industry Average Movement10.1%
Market Average Movement6.9%
10% most volatile stocks in HK Market13.7%
10% least volatile stocks in HK Market3.3%

Stable Share Price: 8247 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: 8247's weekly volatility has decreased from 12% to 2% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1988421Peng Chenhttps://www.sinobio.com.cn

Biosino Bio-Technology and Science Incorporation, together with its subsidiaries, manufactures, sells, and distributes in-vitro diagnostic reagent products in Mainland China. It offers clinical chemistry reagents, including single and double reagents, calibrators, QC products, and washing solution detergents; Elisa kits; time-resolved fluoroimmunoassay analyzers; and flow cytometers and bio chemical analyzers. The company also provides medical and medical inspection services; produces medical instruments; and distributes immunodiagnostic products, biological reagents, and instruments.

Biosino Bio-Technology and Science Incorporation Fundamentals Summary

How do Biosino Bio-Technology and Science Incorporation's earnings and revenue compare to its market cap?
8247 fundamental statistics
Market CapCN¥173.01m
Earnings (TTM)-CN¥1.08m
Revenue (TTM)CN¥355.89m

0.5x

P/S Ratio

-160.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
8247 income statement (TTM)
RevenueCN¥355.89m
Cost of RevenueCN¥212.92m
Gross ProfitCN¥142.98m
Other ExpensesCN¥144.06m
Earnings-CN¥1.08m

Last Reported Earnings

Mar 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.0075
Gross Margin40.17%
Net Profit Margin-0.30%
Debt/Equity Ratio87.0%

How did 8247 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is 8247 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 8247?

Other financial metrics that can be useful for relative valuation.

8247 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.9x
Enterprise Value/EBITDA6.3x
PEG Ration/a

Price to Sales Ratio vs Peers

How does 8247's PS Ratio compare to its peers?

8247 PS Ratio vs Peers
The above table shows the PS ratio for 8247 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average43.8x
690 Uni-Bio Science Group
1.5xn/aHK$477.4m
1228 CANbridge Pharmaceuticals
46.5x51.7%HK$1.7b
6628 Transcenta Holding
32.5x37.8%HK$1.9b
2256 Abbisko Cayman
94.6x58.4%HK$2.5b
8247 Biosino Bio-Technology and Science Incorporation
0.5xn/aHK$202.6m

Price-To-Sales vs Peers: 8247 is good value based on its Price-To-Sales Ratio (0.5x) compared to the peer average (43.8x).


Price to Earnings Ratio vs Industry

How does 8247's PE Ratio compare vs other companies in the HK Biotechs Industry?

Price-To-Sales vs Industry: 8247 is good value based on its Price-To-Sales Ratio (0.5x) compared to the Hong Kong Biotechs industry average (30x)


Price to Sales Ratio vs Fair Ratio

What is 8247's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

8247 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 8247's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of 8247 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 8247 (HK$1.4) is trading below our estimate of fair value (HK$7.45)

Significantly Below Fair Value: 8247 is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 8247's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Biosino Bio-Technology and Science Incorporation forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


52.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biosino Bio-Technology and Science Incorporation has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine whether Biosino Bio-Technology and Science Incorporation is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  • Biosino Bio-Technology and Science Incorporation competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Biosino Bio-Technology and Science Incorporation performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-28.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 8247 is currently unprofitable.

Growing Profit Margin: 8247 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 8247 is unprofitable, and losses have increased over the past 5 years at a rate of 28.2% per year.

Accelerating Growth: Unable to compare 8247's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 8247 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11.3%).


Return on Equity

High ROE: 8247 has a negative Return on Equity (2.44%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Biosino Bio-Technology and Science Incorporation's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 8247's short term assets (CN¥408.1M) exceed its short term liabilities (CN¥389.0M).

Long Term Liabilities: 8247's short term assets (CN¥408.1M) exceed its long term liabilities (CN¥19.3M).


Debt to Equity History and Analysis

Debt Level: 8247's net debt to equity ratio (61.6%) is considered high.

Reducing Debt: 8247's debt to equity ratio has increased from 29.1% to 87% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable 8247 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: 8247 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 27.3% per year.


Discover healthy companies

Dividend

What is Biosino Bio-Technology and Science Incorporation current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 8247's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 8247's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 8247's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 8247's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: 8247 is not paying a notable dividend for the Hong Kong market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 8247 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average board tenure


CEO

Peng Chen (47 yo)

0.50

Tenure

Mr. Chen Peng has been President of Biosino Bio-Technology and Science Incorporation since December 7, 2021. Mr. Chen has ample experience in corporate management chain operational management of high-tech...


Board Members

Experienced Board: 8247's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Biosino Bio-Technology and Science Incorporation's employee growth, exchange listings and data sources


Key Information

  • Name: Biosino Bio-Technology and Science Incorporation
  • Ticker: 8247
  • Exchange: SEHK
  • Founded: 1988
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: HK$202.590m
  • Shares outstanding: 144.71m
  • Website: https://www.sinobio.com.cn

Number of Employees


Location

  • Biosino Bio-Technology and Science Incorporation
  • No. 27, Chaoqian Road
  • Science and Technology Industrial Park
  • Beijing
  • 102200
  • China

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/30 00:00
End of Day Share Price2022/06/29 00:00
Earnings2022/03/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.